Clinical Trial Update: A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya [Phase 1]

View source ↗

Summary

Phase 1 trial completed evaluating safety and immune response of Env-C DNA and Env-C protein vaccines in adults with HIV infections in Kenya; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Env-C DNA vaccine (Env-C DNA vaccine)
• Env-C protein vaccine (Env-C protein vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2025-03-26